Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Charles Conway

Nurse Practitioner Phoenix, AZ Nurse Practitioner

NPI 1801487061 CMS profile 10633400

3540 E Baseline Rd, #130, Phoenix, AZ 85042

Open in the dashboard

General payments

$1,068

56 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Conway of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,068 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2023 General $19 1
2022 General $492 23
2021 General $537 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Conway
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Charles Conway were reported at $20. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Charles Conway Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $537 $135 $40–$426 $132
2022 $492 $152 $48–$470 $149
2023 $19 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $20 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $287 15 payments
  2. AstraZeneca Pharmaceuticals LP $131 3 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $130 6 payments
  4. Lilly USA, LLC $79 6 payments
  5. Amgen Inc. $77 5 payments
  6. AbbVie, Inc. $68 3 payments
  7. Pfizer Inc. $59 4 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $58 3 payments
  9. GlaxoSmithKline, LLC. $40 2 payments
  10. Biohaven Pharmaceuticals, Inc. $33 2 payments
  11. Other $106 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,068 56 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $264 14 payments
  2. Ozempic $181 13 payments
  3. BREZTRI $111 1 payment
  4. JARDIANCE $91 4 payments
  5. Repatha $77 5 payments
  6. TRULICITY $66 5 payments
  7. Otezla $63 4 payments
  8. COLOGUARD DNA CAPTURE REAGENTS $59 4 payments
  9. XIFAXAN $58 3 payments
  10. TRULANCE $58 3 payments
  11. Other $459 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

791

Median for Nurse Practitioner: 389

Drug cost

$7,683

Median for Nurse Practitioner: $21,885

Branded share of claims

41.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Paxlovid Nirmatrelvir/Ritonavir Brand 47 $1,429
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 78 $844
Doxycycline Hyclate Generic 111 $807
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 97 $801
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $726
Methylprednisolone Generic 76 $496
Cephalexin Generic 71 $470
Fluticasone Propionate Generic 39 $363
Cefuroxime Cefuroxime Axetil Brand 32 $326
Valacyclovir Valacyclovir Hcl Brand 12 $266

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$46,800

Of which drugs: $601

Medicare patients

573

Average age 76

Services billed

1,280

386 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 54%
Chronic kidney disease 33%
Ischemic heart disease 27%
Diabetes 25%
Depression 21%
Osteoporosis 20%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older 90714 Office 21 21 $464

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record